BioArctic AB says its partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer’s Association International Conference (AAIC) 2026. The conference is scheduled for July 12–15 in London. The announcement comes from BioArctic, which markets lecanemab in partnership with Eisai. According to the company’s release, the AAIC presentations will include both clinical and real-world findings, and will cover additional analyses related to the treatment’s use. The specific poster or session details, as well as the reported endpoints and study design elements, are expected to be disclosed in conjunction with the conference program.
The information provided in the release is focused on the planned scientific presentations and their setting, rather than on reporting new results ahead of AAIC. The company statement does not indicate any regulatory action or changes to approval status. The details of the data are expected to be presented during the conference dates in London.
